Medication Safety Alert! March 28, 2019
In this week's issue:
- QuarterWatchTM (includes data from Quarter 3, 2018): Focus on Three Psychoactive Drugs: Gabapentin, Pregabalin, and Pimavanserin
- FDA Advise-ERR: Covers still being applied without the cloNIDine patch
- Herceptin Hylecta must be given subcutaneously
- Sidebar: Why are we seeing 4-letter suffixes with new biologics?
- Limited availability of 2,000 mL sterile water bags
The latest issue of ISMP’s QuarterWatch™ (see description in box below) focuses on two older but widely used analogs of the inhibitory gamma-aminobutyric acid (GABA) neurotransmitter and a new type of antipsychotic medication approved for Parkinson’s disease psychosis. Key findings include:
Extensive patterns of potentially unsafe use of the GABA analogs, gabapentin (NEURONTIN, others) and pregabalin (LYRICA)
New questions about both the safety and benefits of pimavanserin (NUPLAZID)
The following is a summary of the full QuarterWatch™ report, which can be found, with additional...